Infectious Disease
Show
- Infectious Disease
- Phase 2 NIH clinical trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins
- A trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease has begun
- 379 0
- Infectious Disease
- NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines
- Most of the allergic reactions to these injections have occurred in those with a history of allergies, of whom many had previously experienced anaphylaxis.
- 610 0
- Genetic Research
- How pathogenic bacteria weather the slings and arrows of infection
- "This work provides a step change in our understanding of the resilience of bacteria as they cause infection."
- 1051 0
- Infectious Disease
- T-Cells Recognize Recent SARS-CoV-2 Variants
- Research determined that SARS-CoV-2-specific CD8+ T-cell responses remained largely intact and could recognize virtually all mutations in the variants studied
- 1410 0
-
- Infectious Disease
- Phase 2 NIH clinical trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins
- A trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease has begun
- 379 0
-
- Infectious Disease
- NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines
- Most of the allergic reactions to these injections have occurred in those with a history of allergies, of whom many had previously experienced anaphylaxis.
- 610 0
-
- Genetic Research
- How pathogenic bacteria weather the slings and arrows of infection
- "This work provides a step change in our understanding of the resilience of bacteria as they cause infection."
- 1051 0
-
- Infectious Disease
- T-Cells Recognize Recent SARS-CoV-2 Variants
- Research determined that SARS-CoV-2-specific CD8+ T-cell responses remained largely intact and could recognize virtually all mutations in the variants studied
- 1410 0
Load More
